locoregionally advanced non-small cell lung cancer
Conditions
Interventions
Case series:Different doses
Sponsors
the Fifth Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Histological or cytologically confirmed unresectable stage IIIA or IIIB (AJCC eighth edition) non-small cell lung cancer patients; 2. Aged 18-65 years old; 3. Untreated patients who have not undergone surgery, chemotherapy, biotherapy or radiation therapy before; 4. Estimated survival time = 3 months; 5. There are evaluable lesions; 6. The body general condition is scored by ECOG: 0-2 score. No major organ dysfunction, oxygen partial pressure = 10.64kPa. White blood cells = 4X10^9/L, hemoglobin = 9.5g/dL; absolute neutrophil count = 1.5X10^9/L; platelet count = 100X10^9/L; total bilirubin = 1.5 times the upper limit of normal level; alanine aminotransferase and cereal Transaminase = 2 times the upper limit of normal level; creatinine = 1.25 times the upper limit of normal level; and creatinine clearance rate = 60ml/min; 7. The patients who can complete follow-up information and can be obtained to understand the situation of the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Stage T3N1M0 patients with contralateral hilar lymph node metastasis, total atelectasis, malignant pleural effusion or pericardial effusion; 2. Patients who do not meet the inclusion criteria of the pathological type, stage and survival status of; 3. Any unstable system is a disease, such as acute infection, major cardiovascular disease which myocardial infarction in the past 1 year is included, any severe liver, kidney or metabolic disease, metabolic disorders; 4. Except the following four malignant tumors which can be radically resected, such as in situ cervical cancer, basal or squamous cell skin cancer, breast intraductal carcinoma in situ, organ-limited prostate cancer, any other malignant tumors within 5 years should be excluded; 5. The investigator believes that patients who may transmit human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) through blood or other body fluids should be excluded; 6. Breastfeeding and / or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test;Liver and kidney function;Clinical physique; | — |
Countries
China
Contacts
Public ContactZhong Lin
Department of Thoracic oncology, The cancer center of the fifth affiliated hospital of Sun Yat-sen University
Outcome results
None listed